CARsgen^® has established in-house GMP-compliant manufacturing capabilities to support vertically integrated CAR T manufacturing, including plasmids, lentiviral vectors, and CAR T-cell production. The vertically integrated production contributes to increased efficiency and enhanced control, resulting in improved drug product consistency and aiming for faster turnaround times for patients. The integrated manufacturing is also expected to help significantly reduce costs and improve margins for more advantageous commercialization.

To further improve the manufacture efficiency, we developed a proprietary platform CARcelerate^® that can shorten the manufacturing time for the CAR T cells to around 30 hours, as compared to the conventional CAR T manufacturing process. The CARcelerate^® platform produces CAR T cells that are younger and are more likely to remain in a ‘naïve’ state and less likely to be exhausted; as such, these CAR T cells from the CARcelerate^® platform are thought to exhibit more potent tumor killing activity.